Reform Biologics LLC, of Woburn, Mass., said it will perform feasibility studies for Bayer AG, of Leverkusen, Germany, using its technologies, in which viscosity-reducing excipients are applied to high-concentration biologic formulations to enable subcutaneous injection or device-assisted administration or to improve filtration unit operations. Financial terms were not disclosed.